Proteomic Insights into Cancer Initiation and Evolution
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 119
Special Issue Editor
2. Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA
Interests: cancer signaling; kinase; phosphorylation; post-translational modifications (PTMs); therapeutic targets; breast cancer; ovarian cancer; drug resistance
Special Issue Information
Dear Colleagues,
Proteomics has emerged as a powerful tool for dissecting the intricate networks of proteins and their interactions, providing insights into how aberrations in protein expression, post-translational modifications, and signaling pathways drive tumorigenesis. This Special Issue will delve into proteomic approaches that unveil the molecular signatures of cancer, identify novel biomarkers, and offer an enhanced understanding of the tumor microenvironment.
From the discovery of subtype-specific biomarkers to uncovering potential therapeutic targets, this Special Issue aims to offer a comprehensive overview of how proteomics is shaping cancer research. We invite authors to submit original research and review articles that focus on the innovative applications of proteomics in unraveling the complexities of cancer biology and translating these findings into clinical advances.
Dr. Xinyan Wu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- proteomic signatures in early cancer detection
- proteomics of tumor microenvironment
- tumor heterogeneity and proteomics
- post-translational modifications and dysregulated signaling pathways driving invasion and metastasis
- biomarker discovery for cancer subtypes
- proteomics and targeted therapies
- single-cell proteomics in cancer research
- proteomics and drug resistance
- clinical applications of proteomics
